The American College of Cardiology on Jan. 13 announced a handful of changes to its executive staff, including promotions and structural changes within the ACC’s senior team.

Redesigning the artificial heart valve could improve blood flow and potentially eliminate the need for blood thinners in patients with mechanical support, according to a new study.

Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.

Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.

The FDA has added at least three additional items to its growing roster of heartburn drug recalls.

Experts at Massachusetts General Hospital have successfully performed five CV transplants using Donation after Circulatory Death donor hearts—the largest number of adult DCD heart transplants ever completed in the U.S.

An analysis of 12 recent randomized clinical trials suggests a majority of patients with ischemic heart disease or a history of MI are eligible for new secondary prevention therapies—a finding that, if acted upon, could change a paradigm that’s been in place for decades.

U.K.-based drug giant AstraZeneca announced Jan. 13 it would be halting its Phase III trial of Epanova, a medication comprised of omega-3 carboxylic acids, early due to disappointing data.

The future of diabetes diagnosis and management could lie in a “smart” LED contact lens, a study published in Nature Reviews Materials suggests.

A group of scientists from the University of Alabama at Birmingham have derived predictive equations to identify adults at a high risk of having nocturnal hypertension or nondipping systolic blood pressure—both hard-to-catch conditions that can raise a person’s risk for CVD.